Avenue Therapeutics to enact reverse stock split
Investing.com | Editor Natashya Angelica
Published Mar 08, 2024 05:02PM ET
In a strategic move, Avenue Therapeutics Inc . (NASDAQ: NASDAQ:ATXI) has announced a reverse stock split, as per a recent 8K SEC filing. Effective Tuesday, the majority of the company's voting capital stockholders granted the board of directors discretionary authority to implement a reverse stock split at a ratio ranging from 30-for-1 to 75-for-1. The exact ratio is yet to be determined by the board.
This decision was made through a written consent from stockholders holding 3,133,886 shares of common stock and 250,000 shares of Class A Preferred Stock. The voting power of Class A Preferred Stock is notably higher, with each share having the equivalent of 194.8 votes as of the date of consent. This collective action represents approximately 56% of the voting power of Avenue Therapeutics' capital stock.
The reverse stock split is intended to be effected by amending the Company's Third Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. The board's approval of both the reverse stock split and the amendment aligns with the stockholders' consent, paving the way for the corporate action.
In compliance with SEC regulations, Avenue Therapeutics will file a Schedule 14C information statement and disseminate it to the company's stockholders. This document will provide further details about the reverse stock split and its implications.
The reverse stock split is a measure often taken by companies to boost the market price of their shares and is typically employed to comply with stock exchange listing requirements or to appeal to a broader range of investors. For Avenue Therapeutics, the execution of this reverse stock split could be a significant step in the company's financial strategy.
The information regarding this corporate action is based on the latest SEC filing by Avenue Therapeutics and reflects the company's current plans as disclosed to the public and its investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.